SIGA Technologies, Inc. (OTCMKTS:SIGA) Director Buys $27,900.00 in Stock

SIGA Technologies, Inc. (OTCMKTS:SIGA) Director Paul G. Savas purchased 5,000 shares of the stock in a transaction dated Friday, November 16th. The shares were acquired at an average price of $5.58 per share, with a total value of $27,900.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of SIGA opened at $5.81 on Thursday. SIGA Technologies, Inc. has a 1 year low of $3.90 and a 1 year high of $8.47.

SIGA Technologies (OTCMKTS:SIGA) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported $4.71 earnings per share for the quarter. The business had revenue of $471.08 million for the quarter.

Hedge funds and other institutional investors have recently modified their holdings of the company. Acuitas Investments LLC raised its position in shares of SIGA Technologies by 52.1% during the 3rd quarter. Acuitas Investments LLC now owns 712,964 shares of the biotechnology company’s stock worth $4,912,000 after acquiring an additional 244,170 shares in the last quarter. Wells Fargo & Company MN acquired a new stake in shares of SIGA Technologies during the 1st quarter worth about $104,000. Rhumbline Advisers acquired a new stake in shares of SIGA Technologies during the 2nd quarter worth about $282,000. Millennium Management LLC acquired a new stake in shares of SIGA Technologies during the 1st quarter worth about $309,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of SIGA Technologies during the 2nd quarter worth about $1,158,000. 6.66% of the stock is currently owned by institutional investors and hedge funds.

Separately, TheStreet upgraded SIGA Technologies from a “d-” rating to a “b” rating in a research note on Monday, November 26th.

ILLEGAL ACTIVITY NOTICE: “SIGA Technologies, Inc. (OTCMKTS:SIGA) Director Buys $27,900.00 in Stock” was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.baseballdailydigest.com/news/2018/12/06/paul-g-savas-purchases-5000-shares-of-siga-technologies-inc-siga-stock.html.

About SIGA Technologies

SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

Featured Story: Hedge Funds – Risk or Reward?

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply